We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksE-therapeutics Regulatory News (ETX)

Share Price Information for E-therapeutics (ETX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 9.75
Bid: 9.55
Ask: 10.50
Change: 0.075 (0.75%)
Spread: 0.95 (9.948%)
Open: 9.75
High: 9.75
Low: 9.75
Prev. Close: 9.95
ETX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Grant of share options and Directors' dealings

23 Nov 2016 16:21

RNS Number : 9836P
e-Therapeutics plc
23 November 2016
 

23 November 2016

 

e-Therapeutics plc

('e-Therapeutics' or 'the Company')

 

Grant of share options and Directors' dealings

 

Oxford and Newcastle, UK, 23 November 2016 - e-Therapeutics plc (AIM: ETX) the drug discovery company, announces that on 23 November 2016 the Company granted options over a total of 10,310,000 ordinary shares of 0.1p each to certain executive directors and other employees (the "Optionholders"). The Optionholders are entitled to exercise their options in three tranches (as set out below) on or after the date specified below, if, at the time of exercise, the prevailing market price of the Company's ordinary shares is not less than the price set out below (the "Exercise Price"). Optionholders will be required to pay the Exercise Price to exercise their options.

Number of shares under option Exercise Price Exercise Date

3,436,666 16.76p 23 November 2018

3,436,667 20.95p 23 November 2018

3,436,667 25.14p 23 November 2019

Details of the individual options granted to executive directors are set out below:

Director Number of shares under option

Steve Medlicott 2,000,000

Sean Nicolson 750,000

The options referred to above are otherwise subject to the Rules of the Company's 2013 Performance Share Plan. 

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

 

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014

1

Details of the person discharging managerial responsibilities/person closely associated

a.

Name

Steve Medlicott

2

Reason for notification

a.

Position/Status

Director

b.

Initial notification/

Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.

Name

e-Therapeutics plc

b.

LEI

N/A

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the financial instrument, type of instrumentIdentification Code

Ordinary shares of 0.1p each 

ISIN: GB00B2823H99

b.

Nature of the transaction

Grant of options to subscribe for ordinary shares

c.

Price(s) and volume(s)

 

 

 

 

 

 

Exercise price(s)

Volume(s)

 

£0.1676

666,666

 

 

£0.2095

666,667

 

 

£0.2514

666,667

 

 

d.

Aggregated information- Aggregated Volume

- Price

 

Volume: 2,000,000 options over ordinary shares

Price: N/A

e.

Date of the transaction

23 November 2016

f.

Place of the transaction

London Stock Exchange

         

 

 

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014

1

Details of the person discharging managerial responsibilities/person closely associated

a.

Name

Sean Nicolson

2

Reason for notification

a.

Position/Status

Director

b.

Initial notification/

Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.

Name

e-Therapeutics plc

b.

LEI

N/A

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the financial instrument, type of instrumentIdentification Code

Ordinary shares of 0.1p each 

ISIN: GB00B2823H99

b.

Nature of the transaction

Grant of options to subscribe for ordinary shares

c.

Price(s) and volume(s)

 

 

Exercise Price(s)

Volume(s)

 

£0.1676

250,000

 

 

£0.2095

250,000

 

 

£0.2514

250,000

 

 

d.

Aggregated information- Aggregated Volume

- Price

 

Volume: 750,000

Price: N/A

e.

Date of the transaction

23 November 2016

f.

Place of the transaction

London Stock Exchange

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DSHLLFLRLTLVFIR
Date   Source Headline
10th Apr 20247:00 amRNSProposed Fundraise of £28.9m and Cancellation
31st Jan 20244:30 pmRNSTotal Voting Rights
24th Jan 202410:04 amRNSExercise of Options and Issue of Equity
16th Jan 20247:00 amRNSBusiness Update
9th Jan 20244:04 pmRNSDirector Dealing and Issue of Equity
27th Dec 20237:00 amRNSUpdate on OTCQX Market Listing
13th Nov 20239:05 amEQSEdison issues update on e-therapeutics (ETX): More to come in RNAi therapy discovery
2nd Nov 20237:00 amRNSStrategic RWE collaboration with Arcturis
26th Oct 20237:38 amRNSInterim results for the six months to 31 July 2023
19th Oct 20239:54 amRNSNotice of Interim Results
20th Sep 20237:00 amRNSSenior Management Update
7th Sep 202311:47 amRNSExercise of Options and Issue of Equity
31st Jul 20234:30 pmRNSTotal Voting Rights
18th Jul 20234:20 pmRNSResult of Annual General Meeting
6th Jul 20235:27 pmRNSDirector Dealing and Issue of Equity
30th Jun 20237:00 amRNSInvestor Presentation
26th Jun 20237:00 amRNSNotice of Investor Presentation
11th May 20237:00 amRNSNotice of AGM and Posting of Annual Report
4th May 20237:00 amRNSFinal results for the year ended 31 January 2023
28th Apr 20234:30 pmRNSTotal Voting Rights
27th Apr 20237:00 amRNSNotification of Full Year Results Date
28th Mar 20233:57 pmRNSExercise of Options and Issue of Equity
21st Feb 20234:35 pmRNSPrice Monitoring Extension
20th Feb 202310:19 amRNSDirector/PDMR Shareholding
7th Feb 20237:00 amRNSFiling of four patent applications
31st Jan 20237:00 amRNSTotal Voting Rights
4th Jan 20233:15 pmRNSDirector Dealing and Issue of Equity
29th Dec 20224:40 pmRNSSecond Price Monitoring Extn
29th Dec 20224:35 pmRNSPrice Monitoring Extension
20th Dec 20224:35 pmRNSPrice Monitoring Extension
31st Oct 20227:00 amRNSTotal Voting Rights
12th Oct 20223:12 pmRNSHolding(s) in Company
11th Oct 202210:42 amRNSHolding(s) in Company
10th Oct 20228:03 amRNSHolding(s) in Company
30th Sep 20227:00 amRNSInterim results for the six months to 31 July 2022
30th Sep 20227:00 amRNSFundraise of £13.5 million by way of Subscription
26th Sep 20224:40 pmRNSSecond Price Monitoring Extn
26th Sep 20224:36 pmRNSPrice Monitoring Extension
1st Aug 20227:00 amRNSFiling of eight patent applications
29th Jul 20227:00 amRNSTotal Voting Rights
20th Jul 202210:39 amRNSResult of Annual General Meeting
6th Jul 20227:00 amRNSNotice to Shareholders - AGM Virtual Access
5th Jul 20227:00 amRNSDirector Dealing and Issue of Equity
17th May 20227:00 amRNSNotice of AGM and Posting of Annual Report
4th May 20227:00 amRNSFinal results for the year ended 31 January 2022
27th Apr 20227:00 amRNSNotification of Full Year Results Date
12th Apr 20227:00 amRNSKey Milestone Achieved on Galapagos Collaboration
5th Apr 20227:00 amRNSImmuno-Oncology Research Collaboration with iTeos
16th Feb 20224:41 pmRNSHolding(s) in Company
16th Feb 202211:47 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.